Abstract:

Objective  To investigate the effects of combination of high-flux hemodialysis (HFD) with hemoperfusion (HP) on the removal of middle and large molecule solutes such as serum fibroblast growth factor 23 (FGF23) and interleukin 6 (IL-6) and the improvement of life quality of patients undergoing maintenance hemodialysis (MHD). Methods  A total of 35 MHD patients were enrolled and underwent two HFD and one HFD+HP per week for 12 months. Indexes such as serum albumin, hemoglobin, phosphorus, calcium, and intact parathyroid hormone (iPTH) were measured every 3 months. Serum FGF23 and IL-6 were detected by ELISA in 0, 6, and 12 months. SF-36 scale was used to evaluate the life quality of patients at the beginning and end of study. Results  A total of 33 patients were followed up for 12 months. The mean age was (59.06±0.64) years and mean dialysis vintage was (178.94±51.50) months. Hemoglobin, pre-albumin, albumin, calcium, phosphorus, and iPTH of patients during follow-up were not significantly different from those before treatment. FGF23 decreased remarkably after being treated for 6 months (P=0.046) and decreased continuously after being treated for 12 months (P=0.006). IL-6 decreased remarkably after being treated for 6 months (P=0.015) and decreased continuously after being treated for 12 months (P=0.015). Scores of all items of MHD patients improved significantly after being followed up for 12 months (P<0.05). Conclusion  HFD+HP can efficiently remove middle and large molecule toxins and is an effect treatment for improving the life quality of MHD patients.

Key words: hemodialysis, hemoperfusion, fibroblast growth factor 23, interleukin 6, quality of life